open access

Vol 13, No 4 (2017)
Case report
Published online: 2017-09-13
Get Citation

Liver metastases of colorectal cancer — what are the limitations of multimodality treatment?

Maciej A. Kawecki, Piotr Piasecki
DOI: 10.5603/OCP.2017.0021
·
Oncol Clin Pract 2017;13(4):172-176.

open access

Vol 13, No 4 (2017)
CASE REPORTS
Published online: 2017-09-13

Abstract

The prognosis of patients with liver-only metastases of colorectal cancer varies significantly, depending mostly
on technical resectability of metastases. Possible treatment modalities include surgical resection, methods of
local ablative treatment, as well as systemic chemotherapy. Hereunder, we present a case of a 52-year-old male
patient with colon cancer metastases limited initially to the liver, who underwent multimodality treatment consisting
of systemic chemotherapy and several forms of localised treatment: radioembolisation, non-anatomical resection
and thermoablation of liver metastases, and wedge resection of lung metastasis. Despite achieving long-lasting
control of liver metastases, localised treatment resulted also in chronic thrombocytopaenia, which prevented
introduction of optimal subsequent systemic treatment.

Abstract

The prognosis of patients with liver-only metastases of colorectal cancer varies significantly, depending mostly
on technical resectability of metastases. Possible treatment modalities include surgical resection, methods of
local ablative treatment, as well as systemic chemotherapy. Hereunder, we present a case of a 52-year-old male
patient with colon cancer metastases limited initially to the liver, who underwent multimodality treatment consisting
of systemic chemotherapy and several forms of localised treatment: radioembolisation, non-anatomical resection
and thermoablation of liver metastases, and wedge resection of lung metastasis. Despite achieving long-lasting
control of liver metastases, localised treatment resulted also in chronic thrombocytopaenia, which prevented
introduction of optimal subsequent systemic treatment.

Get Citation

Keywords

colorectal cancer; metastases; radioisotope therapy; surgery; chemotherapy

About this article
Title

Liver metastases of colorectal cancer — what are the limitations of multimodality treatment?

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 4 (2017)

Article type

Case report

Pages

172-176

Published online

2017-09-13

DOI

10.5603/OCP.2017.0021

Bibliographic record

Oncol Clin Pract 2017;13(4):172-176.

Keywords

colorectal cancer
metastases
radioisotope therapy
surgery
chemotherapy

Authors

Maciej A. Kawecki
Piotr Piasecki

References (12)
  1. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386–1422.
  2. Fong Y, Fortner J, Sun R, et al. Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery. 1999; 230(3): 309.
  3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 2013; 14(12): 1208–1215.
  4. Ruers T, Punt C, Coevorden FV, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Annals of Oncology. 2012; 23(10): 2619–2626.
  5. Scorsetti M, Arcangeli S, Tozzi A, et al. Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2013; 86(2): 336–342.
  6. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012; 32(4): 1387–1395.
  7. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(15): 1723–1731.
  8. Sharma RA, Wasan HS, Van Ha, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. Journal of Clinical Oncology. 2017;35(15_suppl. (suppl.3507): 3507.
  9. Ye LC, Liu TS, Ren Li, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013; 31(16): 1931–1938.
  10. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015; 26(4): 702–708.
  11. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229–237.
  12. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10): 1065–1075.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl